A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Robotic-Assisted Lung Transplant Completed

Robotic-Assisted Surgery Means Less Pain and Quicker Healing for Patients

Robotic-Assisted Lung Transplant: Cardiothoracic surgeons in the Smidt Heart Institute at Cedars-Sinai recently performed a groundbreaking robotic-assisted lung transplant.

With a new right lung, the patient, a 69-year-old man from Claremont, California, is back to exercising and chasing his grandchildren after eight years of declining health and mobility as well as breathing difficulties.

View video here.

“We believe robotic-assisted surgery is the future of lung transplantation,” said Dominic Emerson, MD, the lead surgeon and associate surgical director of Heart Transplant and Mechanical Circulatory Support in the Smidt Heart Institute.

“Over the past two years, we have transitioned from offering traditional lung transplantation to minimally invasive lung transplantation to now, robotic-assisted capabilities. This long-awaited achievement is the start of a new era of cardiothoracic care.”

Prior to pioneering the world’s first robotically assisted lung transplant, surgeons in the Smidt Heart Institute also developed new, minimally invasive techniques that speed healing and shorten hospital stays.

“Our team pioneered the utilization of smaller incisions for lung transplant, so much so that most incisions are no bigger than the short side of a driver’s license,” said Emerson, an assistant professor of cardiac surgery. “Smaller incisions reduce postoperative pain and improve recovery for our patients.”

Unlike routine lung transplantations, where surgeons usually create a “clamshell” incision which involves cutting apart the breastbone, the Smidt Heart Institute developed a technique requiring only a small incision between the ribs—just large enough to remove a patient’s old, deflated lungs and then, insert and inflate the new donor lungs.

In addition to this technique, during the robotic lung transplant, surgeons used the robotic device to enter the body via two small “portholes” on the side of the body. These small portholes are utilized during all lung transplant surgeries to place chest drains at the end of surgery, which are later removed.

Pedro Catarino, MD “With the robotic surgery, we still make the same incisions we make for our minimally invasive technique,” said Pedro Catarino, MD,  director of Aortic Surgery in the Smidt Heart Institute. “The difference is that instead of a surgeon placing their hands in the incision between the ribs to complete the surgery, the robotic device enters via the portholes.”


Catarino, widely recognized as an expert in minimally invasive lung transplantation techniques, scrubbed in alongside Emerson and Dominick Megna, MD, surgical director of the Lung Transplant Program at Cedars-Sinai, to perform the robotic surgery.

The robotic arms, Catarino said, allow for a great deal of movement and manipulation.

“The less movement inside a patient’s body, the less pain there will be post-surgery and the faster recovery times will be,” said Catarino.

In addition to less pain and recovery time for a patient, the robotic procedure has its perks for surgeons, too.

“The visualization used with the robotic device is just so good,” said Emerson. “You can see the airway and blood vessels in ways that are unparalleled. The high-definition, 3-D technology showcases details you would never see normally. It was a remarkable experience—something I will always remember.”

Joanna Chikwe, MD, founding chair of the Department of Cardiac Surgery, noted that the new methods allow the team to help more patients. In 2020, the team performed 18 lung transplants. In 2021, they completed 60.

“Smaller incisions and better visualization lead to better outcomes in the right patients,” said Chikwe. “In addition to surgical advances, we have several research opportunities in the pipeline and plan on big changes in the coming year—changes that will improve every aspect of transplantation for patients.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy